TYRA Tyra Biosciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1863127 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-52.1%
TTM EPS YoY-39.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-34.9%
ROA-33.0%
ROIC (approx.)-63.3%
Asset turnover—
Leverage & solvency
Liabilities / assets4.8%
Debt / equity0.00x
Current ratio23.93x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.70x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $43.14M | $39.20M | $33.47M | $28.19M | $25.47M | $24.31M | $24.96M | $22.18M |
| SG&A expense | $11.74M | $9.81M | $8.53M | $8.33M | $7.47M | $7.14M | $6.89M | $7.56M |
| Operating income | -$54.88M | -$49.00M | -$42.00M | -$36.52M | -$32.94M | -$31.45M | -$31.85M | -$29.74M |
| Net income | -$51.12M | -$45.56M | -$39.30M | -$33.83M | -$29.87M | -$28.10M | -$28.15M | -$25.57M |
| EBITDA | -$54.76M | -$48.87M | -$41.86M | -$36.38M | -$32.81M | -$31.31M | -$31.71M | -$29.60M |
| EPS (basic) | -0.74 | -0.69 | -0.64 | — | -0.50 | -0.47 | -0.47 | — |
| EPS (diluted) | -0.74 | -0.69 | -0.64 | — | -0.50 | -0.47 | -0.47 | — |
| Weighted avg. shares (diluted) | 69.08M | 65.99M | 61.75M | — | 59.67M | 59.55M | 59.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $456.02M | $73.83M | $84.95M | $77.39M | $61.95M | $98.49M | $100.72M | $92.97M |
| Current assets | $711.62M | $366.97M | $394.61M | $265.45M | $281.22M | $302.15M | $324.57M | $347.46M |
| PP&E, net | $1.08M | $1.17M | $1.22M | $1.31M | $1.35M | $1.41M | $1.52M | $1.65M |
| Total assets | $727.53M | $383.36M | $412.04M | $282.61M | $301.85M | $321.50M | $343.48M | $363.56M |
| Current liabilities | $29.74M | $24.62M | $19.26M | $18.09M | $15.88M | $13.77M | $14.25M | $14.59M |
| Total liabilities | $34.68M | $29.70M | $24.46M | $23.43M | $21.34M | $19.35M | $19.94M | $20.41M |
| Shareholders' equity | $692.84M | $353.66M | $387.57M | $259.18M | $280.51M | $302.15M | $323.53M | $343.15M |
| Shares outstanding | 68.98M | 59.66M | 59.47M | 53.71M | 53.32M | 53.23M | 53.09M | 50.75M |
| Cash flow statement | ||||||||
| Operating cash flow | -$32.21M | -$31.08M | -$32.57M | -$23.62M | -$22.38M | -$23.68M | -$25.46M | -$19.59M |
| Capital expenditure | $90,000 | $66,000 | $88,000 | $57,000 | $39,000 | $31,000 | $14,000 | $6,000 |
| Free cash flow | -$32.30M | -$31.14M | -$32.66M | -$23.68M | -$22.42M | -$23.71M | -$25.47M | -$19.60M |
| Investing cash flow | $34.92M | $17.85M | -$120.24M | $34.38M | -$14.81M | $20.87M | $32.03M | $6.96M |
| Financing cash flow | $379.47M | $2.10M | $160.38M | $4.68M | $647,000 | $583,000 | $2.19M | $706,000 |
| Depreciation & amortization | $130,000 | $138,000 | $138,000 | $132,000 | $131,000 | $140,000 | $143,000 | $144,000 |
| Stock-based compensation | $12.16M | $10.23M | $7.85M | $7.63M | $7.58M | $6.38M | $6.42M | $6.70M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.